Head and Neck Cancer Market, By Drug Class (EGFR Inhibitors, Mitotic, Inhibitors, Anti-PD-1 Monoclonal Antibodies, and Others (Docetaxel, fluorouracil)), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI55619 | Publish Date: March 2024 | No. of Pages: 178

Global Head And Neck Market Companies

  • Sanofi S.A.
  • Pfizer Inc.
  • Eli Lilly and Company
  • MERCK Kommanditgesellschaft auf Aktien
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Galera Therapeutics Inc.
  • Fresenius Kabi AG
  • Teva Pharmaceuticals Industries Limited

Recent News:

  • Eisai introduced "Made of More," a new program in April 2023, to support and encourage community among people with head and neck cancer. The company is sharing the personal stories of those impacted by this disease, which is often ignored and accounts for only 4% of all cancer cases in the U.S., in partnership with organizations like the Head and Neck Cancer Alliance, Support for People with Oral and Head and Neck Cancer, the Thyroid, Head and Neck Cancer Foundation, and CancerCare.
  • The International Centre for Recurrent Head & Neck Cancer (IReC) assembled a collection of distinguished medical professionals and researchers in July 2022 to advance the condition's research. IReC also aims to set global standards for supportive care, palliative care, and curative treatment of recurrent head and neck cancer to improve patient outcomes both domestically and internationally.